Back to Search
JOEL KEATS, MD
MD
Diagnostic Radiology Physician
NPI: 1225018393Individual
Specialties, Licenses & Credentials
Diagnostic Radiology PhysicianPrimary
Radiology — Diagnostic Radiology
Code: 2085R0202X
MD019313E(PA)C35344(CA)
Research & Publications (20)
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
PMID 17692805·Cancer Cell·2007
8-other
Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.
PMID 17107900·Leuk Lymphoma·2006
6-review
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.
PMID 15677557·Blood·2005
8-other
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
PMID 12393535·Blood·2003
8-other
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.
PMID 19572547·J Med Chem·2009
7-preclinical
High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas.
PMID 19362969·Clin Lymphoma Myeloma·2009
8-other
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia.
PMID 19351844·Cancer Res·2009
8-other
Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.
PMID 19096011·Blood·2009
7-preclinical
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling.
PMID 18997792·Nat Immunol·2008
7-preclinical
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.
PMID 18691885·Bioorg Med Chem Lett·2008
4-observational
Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.
PMID 18567838·Blood·2008
5-case
Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells.
PMID 18297535·Leuk Lymphoma·2008
8-other
SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity.
PMID 18179464·Chem Biol Drug Des·2008
8-other
The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
PMID 18076711·Br J Haematol·2008
7-preclinical
Crystal structure of the T315I mutant of AbI kinase.
PMID 17718712·Chem Biol Drug Des·2007
7-preclinical
Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution.
PMID 17568814·Leukemia·2007
8-other
Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
PMID 16492148·Chem Biol Drug Des·2006
4-observational
AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes.
PMID 16373705·Mol Cancer Ther·2005
7-preclinical
Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity.
PMID 15705883·Cancer Res·2005
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1520 SAN PABLO ST
LOS ANGELES, CA 90033 - Phone
- (323) 442-7450
Quick Facts
- NPI
- 1225018393
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile